clinical trial

[Genprex, Inc.] Genprex, Inc. announced that the first patient was dosed in the Acclaim-1 clinical trial, an open-label, multi-center Phase I/II clinical trial evaluating REQORSA™ Immunogene Therapy, in combination with Tagrisso® (osimertinib) in patients with late-stage NSCLC.

[Biohaven Pharmaceutical Holding Company Ltd.] Biohaven Pharmaceutical Holding Company Ltd. announced that it entered into a license agreement with Bristol Myers Squibb for the development and commercialization rights to taldefgrobep alfa, a novel, Phase III-ready anti-myostatin adnectin.

[Nature News] Two years into the pandemic, the COVID-19 drugs pipeline is primed to pump out novel treatments — and fresh uses for familiar therapies.

[University of Utah] University of Utah (U of U) Health researchers will leading a five-year, $22-million nationwide clinical trial for NMDA receptor encephalitis––a type of autoimmune encephalitis that prompts the immune system to mistakenly attack the brain, causing confusion, memory loss, seizures, and symptoms similar to bipolar disorder and other psychiatric conditions.

[Akeso, Inc. (BioSpace, Inc.)] -Akeso, Inc. announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. to establish a clinical trial partnership to jointly conduct a Phase Ib/II clinical trial of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-(L)1 inhibitor treatment regimen for extensive stage small cell lung cancer.

[LEXEO Therapeutics] LEXEO Therapeutics announced positive initial expression and biomarker data from the low-dose cohort of its ongoing Phase I/II clinical trial of LX1001, an adeno-associated virus (AAV)-based investigational gene therapy designed to deliver the protective apolipoprotein E2 gene into the CNS of APOE4 homozygous Alzheimer’s disease patients.